Login Register Cart 0
Generic placeholder image

Current Women`s Health Reviews

Editor-in-Chief

ISSN (Print): 1573-4048
ISSN (Online): 1875-6581

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Efficacy of N-acetylcysteine as Add-on Therapy for the Management of Chronic Pelvic Pain Syndrome in Women

Author(s): Maede Mohseni, Somayeh Rahimi, Mahtabalsadat Mirjalili, Younes Mohammadi and Maryam Mehrpooya*

Volume 20, Issue 1, 2024

Published on: 08 February, 2023

Article ID: e301222212300 Pages: 10

DOI: 10.2174/1573404819666221230145013

Price: $65

Abstract

Objective: Considering supportive evidence on N-acetylcysteine (NAC) effectiveness in neuropathic pain syndromes, we conducted this study to evaluate its effect on women suffering from chronic pelvic pain syndrome (CPPS).

Methods: In a randomized, double-blind study, 106 women with CPPS were assigned to receive NAC+amitriptyline or placebo+amitriptyline treatment. Amitriptyline was administrated at a dose of 25 mg/daily and NAC and placebo at 600 mg twice daily. The effect of treatment was assessed on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and its domain scores, including pain, urinary symptoms, and quality of life impact scores at weeks 4 and 8 after treatment. The global response was also assessed on the 7-point patient-reported global response assessment (GRA) scale at the end of the study.

Results: By week 4, comparative improvements were noticed in the two groups' NIH-CPSI total score and domain scores. From week 4 to week 8, we noted the superior efficacy of NAC+amitriptyline treatment over placebo+amitriptyline in improving the NIH-CPSI total score and its domain scores, as the proportion of patients responding to treatment (the subjects with ≥ 6-point reduction in the total NIH-CPSI score), as well those reporting marked or moderate improvements in their overall symptoms on GRA was significantly more significant in patients receiving NAC+amitriptyline treatment relative to those receiving placebo+amitriptyline treatment.

Conclusion: These findings provided preliminary evidence regarding the possible role of NAC as an adjunct therapy in the management of CPPS in women, which needs to be validated in future studies.

Keywords: Inflammation, oxidative stress, neuropathic pain syndrome, chronic pelvic pain syndrome, N-acetylcysteine, global response assessment.

Graphical Abstract

[1]
Speer LM, Mushkbar S, Erbele T. Chronic pelvic pain in women. Am Fam Physician 2016; 93(5): 380-7.
[PMID: 26926975]
[2]
Ahangari A. Prevalence of chronic pelvic pain among women: An updated review. Pain Physician 2014; 2(17): E141-7.
[http://dx.doi.org/10.36076/ppj.2014/17/E141] [PMID: 24658485]
[3]
Ayorinde AA, Bhattacharya S, Druce KL, Jones GT, Macfarlane GJ. Chronic pelvic pain in women of reproductive and post-reproductive age: A population-based study. Eur J Pain 2017; 21(3): 445-55.
[http://dx.doi.org/10.1002/ejp.938] [PMID: 27634190]
[4]
Mathias S, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: Prevalence, health-related quality of life, and economic correlates. Obstet Gynecol 1996; 87(3): 321-7.
[http://dx.doi.org/10.1016/0029-7844(95)00458-0] [PMID: 8598948]
[5]
Ghaly AFF, Chien PW. Chronic pelvic pain: Clinical dilemma or clinician’s nightmare. Sex Transm Infect 2000; 76(6): 419-25.
[http://dx.doi.org/10.1136/sti.76.6.419] [PMID: 11229349]
[6]
Grinberg K, Sela Y, Nissanholtz-Gannot R. New insights about Chronic Pelvic Pain Syndrome (CPPS). Int J Environ Res Public Health 2020; 17(9): 3005.
[http://dx.doi.org/10.3390/ijerph17093005] [PMID: 32357440]
[7]
Breser ML, Salazar FC, Rivero VE, Motrich RD. Immunological mechanisms underlying chronic pelvic pain and prostate inflammation in chronic pelvic pain syndrome. Front Immunol 2017; Jul 31 8: 898.
[8]
Antolak S. Chronic pelvic pain: The peripheral neuropathic basis Scientific American Pain Management. Hamilton, ON Decker Intellectual Properties 2017.
[9]
Patil S, Daniel G, Vyas R, et al. Neuromuscular treatment approach for women with chronic pelvic pain syndrome improving pelvic pain and functionality. Neurourol Urodyn 2022; 41(1): 220-8.
[http://dx.doi.org/10.1002/nau.24799] [PMID: 34529875]
[10]
Aldini G, Altomare A, Baron G, et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: The reasons why. Free Radic Res 2018; 52(7): 751-62.
[http://dx.doi.org/10.1080/10715762.2018.1468564] [PMID: 29742938]
[11]
Sadowska AM, Manuel-y-Keenoy B, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: Discordant in vitro and in vivo dose-effects: A review. Pulm Pharmacol Ther 2007; 20(1): 9-22.
[http://dx.doi.org/10.1016/j.pupt.2005.12.007] [PMID: 16458553]
[12]
Schwalfenberg GK. N-acetylcysteine: A review of clinical usefulness (an old drug with new tricks). J Nutr Metab 2021; 2021: 9949453.
[13]
Sözbir E, Nazıroğlu M. Diabetes enhances oxidative stress-induced TRPM2 channel activity and its control by N-acetylcysteine in rat dorsal root ganglion and brain. Metab Brain Dis 2016; 31(2): 385-93.
[http://dx.doi.org/10.1007/s11011-015-9769-7] [PMID: 26612073]
[14]
Naik AK, Tandan SK, Dudhgaonkar SP, et al. Role of oxidative stress in pathophysiology of peripheral neuropathy and modulation by N-acetyl-l-cysteine in rats. Eur J Pain 2006; 10(7): 573-9.
[http://dx.doi.org/10.1016/j.ejpain.2005.08.006] [PMID: 16214382]
[15]
Liu Y, Ni Y, Zhang W, Sun YE, Ma Z, Gu X. N-acetyl-cysteine attenuates remifentanil-induced postoperative hyperalgesia via inhibiting matrix metalloproteinase-9 in dorsal root ganglia. Oncotarget 2017; 8(10): 16988-7001.
[http://dx.doi.org/10.18632/oncotarget.15217] [PMID: 28199982]
[16]
Mohiuddin M, Pivetta B, Gilron I, Khan JS. Efficacy and safety of N-acetylcysteine for the Management of Chronic Pain in adults: A systematic review and meta-analysis. Pain Med 2021; 22(12): 2896-907.
[http://dx.doi.org/10.1093/pm/pnab042] [PMID: 33560443]
[17]
Wang LL, Huang YH, Yan CY, et al. N-acetylcysteine ameliorates prostatitis via miR-141 regulating Keap1/Nrf2 signaling. Inflammation 2016; 39(2): 938-47.
[http://dx.doi.org/10.1007/s10753-016-0327-1] [PMID: 26941030]
[18]
Gorpynchenko I, Nurimanov K, Poroshina T, Savchenko V, Drannik G, Dubuske L. The clinical and immunologic effects of acetylcysteine in the treatment of chronic abacterial prostatitis. J Allergy Clin Immunol 2020; 145(2): AB30.
[http://dx.doi.org/10.1016/j.jaci.2019.12.821]
[19]
Lete I, Mendoza N, de la Viuda E, Carmona F. Effectiveness of an antioxidant preparation with N-acetyl cysteine, alpha lipoic acid and bromelain in the treatment of endometriosis-associated pelvic pain: LEAP study. Eur J Obstet Gynecol Reprod Biol 2018; 228: 221-4.
[http://dx.doi.org/10.1016/j.ejogrb.2018.07.002] [PMID: 30007250]
[20]
Yaryari Am, Mousavibahar SH, Amirhassani S, Bagheri M, Mohammadi Y, Mehrpooya M. Men suffering from category III chronic prostatitis may benefit from N‐acetylcysteine as an adjunct to alpha‐blockers. LUTS: Lower Urinary Tract Symptoms 2022; 14(3): 199-207.
[http://dx.doi.org/10.1111/luts.12425]
[21]
Litwin MS. Mcnaughton-collins Mary, Fowler FJ Jr, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. J Urol 1999; 162(2): 369-75.
[http://dx.doi.org/10.1016/S0022-5347(05)68562-X] [PMID: 10411041]
[22]
Allameh F, Mansouri Tehrani MM, Tasharrofi MA, Ganji Jameshouran MA. Validation of the Persian version of the National Institute of health chronic prostatitis symptom index. Urol J 2020; 18(1): 117-21.
[PMID: 32149374]
[23]
Marszalek M, Wehrberger C, Temml C, Ponholzer A, Berger I, Madersbacher S. Chronic pelvic pain and lower urinary tract symptoms in both sexes: Analysis of 2749 participants of an urban health screening project. Eur Urol 2009; 55(2): 499-508.
[http://dx.doi.org/10.1016/j.eururo.2008.03.073] [PMID: 18395963]
[24]
Piontek K, Ketels G, Albrecht R, et al. Somatic and psychosocial determinants of symptom severity and quality of life in male and female patients with chronic pelvic pain syndrome. J Psychosom Res 2019; 120: 1-7.
[http://dx.doi.org/10.1016/j.jpsychores.2019.02.010] [PMID: 30929698]
[25]
Propert KJ, Alexander RB, Nickel JC, et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology 2002; 59(6): 870-6.
[http://dx.doi.org/10.1016/S0090-4295(02)01601-1] [PMID: 12031372]
[26]
Horst A, de Souza J. Effects of N-acetylcysteine on spinal cord oxidative stress biomarkers in rats with neuropathic pain. Braz J Med Biol Res 2017; 50(12): e6533.
[27]
Carrasco C, Naziroǧlu M, Rodríguez AB, Pariente JA. Neuropathic pain: Delving into the oxidative origin and the possible implication of transient receptor potential channels. Front Physiol 2018; 9: 95.
[http://dx.doi.org/10.3389/fphys.2018.00095] [PMID: 29491840]
[28]
Grace PM, Tawfik VL, Svensson CI, Burton MD, Loggia ML, Hutchinson MR. The neuroimmunology of chronic pain: From rodents to humans. J Neurosci 2021; 41(5): 855-65.
[http://dx.doi.org/10.1523/JNEUROSCI.1650-20.2020] [PMID: 33239404]
[29]
Šutulović N, Grubač Ž, Šuvakov S, et al. Experimental chronic prostatitis/chronic pelvic pain syndrome increases anxiety-like behavior: The role of brain oxidative stress, serum corticosterone, and hippocampal parvalbumin-positive interneurons. Oxid Med Cell Longev 2021; 2021
[30]
Ihsan AU, Khan FU, Khongorzul P, et al. Role of oxidative stress in pathology of chronic prostatitis/chronic pelvic pain syndrome and male infertility and antioxidants function in ameliorating oxidative stress. Biomed Pharmacother 2018; 106: 714-23.
[http://dx.doi.org/10.1016/j.biopha.2018.06.139] [PMID: 29990863]
[31]
Kaushik AS, Strath LJ, Sorge RE. Dietary interventions for treatment of chronic pain: oxidative stress and inflammation. Pain Ther 2020; 9(2): 487-98.
[http://dx.doi.org/10.1007/s40122-020-00200-5] [PMID: 33085012]
[32]
Deng GC, Lu M, Zhao YY, Yuan Y, Chen G. Activated spinal astrocytes contribute to the later phase of carrageenan-induced prostatitis pain. J Neuroinflammation 2019; 16(1): 189.
[http://dx.doi.org/10.1186/s12974-019-1584-3] [PMID: 31653262]
[33]
Horst A, Kolberg C, Moraes MS, et al. Effect of N-acetylcysteine on the spinal-cord glutathione system and nitric-oxide metabolites in rats with neuropathic pain. Neurosci Lett 2014; 569: 163-8.
[http://dx.doi.org/10.1016/j.neulet.2014.03.063] [PMID: 24704379]
[34]
Elberry AA, Sharkawi SMZ, Wahba MR. Antinociceptive and anti-inflammatory effects of N-acetylcysteine and verapamil in Wistar rats. Korean J Pain 2019; 32(4): 256-63.
[http://dx.doi.org/10.3344/kjp.2019.32.4.256] [PMID: 31569917]
[35]
Bernabucci M, Notartomaso S, Zappulla C, et al. N-Acetyl-cysteine causes analgesia by reinforcing the endogenous activation of type-2 metabotropic glutamate receptors. Molecular pain 2012; Oct 23 8: 77.
[http://dx.doi.org/10.1186/1744-8069-8-77]
[36]
Bardoni R. Role of presynaptic glutamate receptors in pain transmission at the spinal cord level. Curr Neuropharmacol 2013; 11(5): 477-83.
[http://dx.doi.org/10.2174/1570159X11311050002] [PMID: 24403871]
[37]
Chiechio S, Nicoletti F. Metabotropic glutamate receptors and the control of chronic pain. Curr Opin Pharmacol 2012; 12(1): 28-34.
[http://dx.doi.org/10.1016/j.coph.2011.10.010] [PMID: 22040745]
[38]
Moussawi K, Pacchioni A, Moran M, et al. N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat Neurosci 2009; 12(2): 182-9.
[http://dx.doi.org/10.1038/nn.2250] [PMID: 19136971]
[39]
Li J, Xu L, Deng X, et al. N-acetyl-cysteine attenuates neuropathic pain by suppressing matrix metalloproteinases. Pain 2016; 157(8): 1711-23.
[http://dx.doi.org/10.1097/j.pain.0000000000000575] [PMID: 27075430]
[40]
Ji RR, Xu ZZ, Wang X, Lo EH. Matrix metalloprotease regulation of neuropathic pain. Trends Pharmacol Sci 2009; 30(7): 336-40.
[http://dx.doi.org/10.1016/j.tips.2009.04.002] [PMID: 19523695]
[41]
Heidari N, Sajedi F, Mohammadi Y, Mirjalili M, Mehrpooya M. Ameliorative effects of N-acetylcysteine as adjunct therapy on symptoms of painful diabetic neuropathy. J Pain Res 2019; 12: 3147-59.
[http://dx.doi.org/10.2147/JPR.S228255] [PMID: 31819599]
[42]
Batooei M, Tahamoli-Roudsari A, Basiri Z, et al. Evaluating the effect of oral N-acetylcysteine as an adjuvant treatment on clinical outcomes of patients with rheumatoid arthritis: A randomized, double blind clinical trial. Rev Recent Clin Trials 2018; 13(2): 132-8.
[http://dx.doi.org/10.2174/1574887113666180307151937] [PMID: 29521247]
[43]
Hashemi G, Mirjalili M, Basiri Z, et al. A pilot study to evaluate the effects of oral N-acetyl cysteine on inflammatory and oxidative stress biomarkers in rheumatoid arthritis. Curr Rheumatol Rev 2019; 15(3): 246-53.
[http://dx.doi.org/10.2174/1573403X14666180926100811] [PMID: 30255760]

Rights & Permissions Print Cite
Article Metrics
11
1
© 2024 Bentham Science Publishers | Privacy Policy